- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Nebulization with hypertonic saline effective in infants with bronchiolitis
Nebulized hypertonic saline may somewhat improve the clinical severity score and shorten the length of stay in infants hospitalized with acute bronchiolitis, says an article published in the Cochrane Database of Systematic Reviews.
In babies with acute viral bronchiolitis, airway edema (swelling) and mucus clogging are the main pathogenic characteristics. These pathological alterations and airway blockage may be lessened by inhaling a hypertonic saline solution ( 3%) solution. This review was originally published in 2008 and has since been updated in 2010, 2013, and 2017. In order to determine the effects of nebulized hypertonic ( 3%) saline solution in babies with acute bronchiolitis, Linjie Zhang and team carried out this investigation.
On January 13, 2022, searches were conducted for Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Epub Ahead of Print, MEDLINE, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily, LILACS, Embase, CINAHL, and Web of Science. Children under 24 months old with acute bronchiolitis were included in randomized controlled trials (RCTs) and quasi-RCTs that used nebulized hypertonic saline alone or in combination with bronchodilators as an active intervention and nebulized 0.9% saline or normal care as a comparator. Length of hospital stay was the main result of inpatient trials, whereas rate of hospitalization was the main result of outpatient or emergency department (ED) trials.
The key findings of this study were:
1. Compared to infants treated with nebulized normal (0.9%) saline or standard care, hospitalized infants treated with nebulized hypertonic saline may experience a shorter mean length of hospital stay.
2. In the first three days of treatment, infants who received hypertonic saline might also have post-inhalation clinical scores that were lower than those of infants who received normal saline.
3. When compared to nebulized normal saline, nebulised hypertonic saline may reduce the chance of hospitalization by 13% in infants who were treated as outpatients or in the emergency department.
4. Up to 28 days following release, hypertonic saline may not, however, lower the likelihood of readmission to the hospital.
5. Twenty-seven trials provided safety data: 14 reported no adverse events, 13 reported at least one adverse event, the majority of which were minor and went away on their own (low certainty evidence).
6. The adverse events included worsening cough, bronchospasm, agitation, bradycardia, vomiting, desaturation, and diarrhea.
Nebulized hypertonic saline therapy may also lower outpatient and ED patients' likelihood of hospitalization. When combined with a bronchodilator, nebulized hypertonic saline appears to be a safe treatment for infants with bronchiolitis, with relatively minimal and spontaneously resolved adverse effects. Due mostly to inconsistency and the possibility of bias, the certainty of the evidence ranged from low to very low for all outcomes.
Reference:
Zhang, L., Mendoza-Sassi, R. A., Wainwright, C. E., Aregbesola, A., & Klassen, T. P. (2023). Nebulised hypertonic saline solution for acute bronchiolitis in infants. In Cochrane Database of Systematic Reviews (Vol. 2023, Issue 4). Wiley. https://doi.org/10.1002/14651858.cd006458.pub5
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751